RxDoctor Payments Data

Peter Morcos, MD

Cardiovascular Disease · la Mesa, CANPI 1922207430

Payments from drug & device makers

$2,910in general payments, 2019–2025

Across 161 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$490
  • Pfizer$397
  • Amgen$357
  • Johnson & Johnson$141
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$141
  • GSK$131
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,910 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$360,149
Medicare patients
2,772
Services billed
5,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$190,285
EntrestoSacubitril/Valsartan119$162,053
FarxigaDapagliflozin Propanediol117$116,238
JardianceEmpagliflozin62$77,824
XareltoRivaroxaban26$37,244
Repatha SureclickEvolocumab41$33,000
OzempicSemaglutide12$22,668
Praluent PenAlirocumab24$18,601
Ezetimibe111$4,352
Metoprolol Succinate248$3,832
Rosuvastatin Calcium212$3,463
Atorvastatin Calcium222$2,499
Bumetanide43$2,369
Ranolazine ErRanolazine23$2,227
Diltiazem 24hr Er (Cd)Diltiazem Hcl85$1,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$397$190,285162 claims
NovartisEntresto$490$162,053119 claims
AstraZenecaFarxiga$49$116,238117 claims
Boehringer IngelheimJardiance$125$77,82462 claims
Johnson & JohnsonXarelto$141$37,24426 claims
Novo NordiskOzempic$16$22,66812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →